Browse by author
Lookup NU author(s): David Rawlings, Dr Claire WoodORCiD, Professor Timothy Cheetham, Dr Cecilia Jimenez MorenoORCiD, Dr Anna Mayhew, Dr Michelle Eagle, Professor Michela GuglieriORCiD, Professor Volker StraubORCiD, Emerita Professor Katherine Bushby, Dr Anna Sarkozy
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
IntroductionWe assessed prophylactic use of bisphosphonate (BP) in Duchenne muscular dystrophy (DMD) patients on glucocorticoid (GC) therapy.MethodsFifty-two DMD patients on daily GC were offered BP (oral risedronate). Patients were reviewed for tolerability, side effects, bone pain, and fracture frequency. Bone mineral density (BMD) was determined by annual dual energy X-ray absorptiometry. BP-treated patients were compared with 15 BP-naive patients (untreated cohort).ResultsSide effects occurred in 9 patients. Thirty-six patients continued BP therapy for over 12 months (mean, 3.6 years). Five treated patients reported bone pain. Three treated patients suffered a vertebral fracture, significantly less than in the untreated cohort (5/15). Lumbar spine adjusted BMD Z-scores remained unchanged in treated patients and were significantly greater than in the untreated cohort.ConclusionsProphylactic oral risedronate therapy was tolerated by most DMD patients. It appears to maintain BMD and may reduce fracture rate in DMD patients on GC. Muscle Nerve54: 79-85, 2016
Author(s): Srinivasan R, Rawlings D, Wood CL, Cheetham T, Moreno ACJ, Mayhew A, Eagle M, Guglieri M, Straub V, Owen C, Bushby K, Sarkozy A
Publication type: Article
Publication status: Published
Journal: Muscle & Nerve
Year: 2016
Volume: 54
Issue: 1
Pages: 79-85
Print publication date: 01/07/2016
Online publication date: 27/04/2016
Acceptance date: 20/11/2015
ISSN (print): 0148-639X
ISSN (electronic): 1097-4598
Publisher: Wiley-Blackwell
URL: http://dx.doi.org/10.1002/mus.24991
DOI: 10.1002/mus.24991
Altmetrics provided by Altmetric
